{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"}]}],"title":"Anti-HPV 6 (N=11, N=21, N=22)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"22"}]}],"title":"Anti-HPV 11 (N=11, N=21, N=22)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"24"}]}],"title":"Anti-HPV 16 (N=11, N=23, N=24)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"}]}],"title":"Anti-HPV 18 (N=11, N=24, N=24)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"}]}],"title":"Anti-HPV 31 (N=11, N=24, N=23)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"25"}]}],"title":"Anti-HPV 45 (N=11, N=26, N=25)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"25"}]}],"title":"Anti-HPV 52 (N=9, N=23, N=25)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"}]}],"title":"Anti-HPV 58 (N=10, N=24, N=22)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"30"}],"units":"Participants"}],"description":"A vaccinated participant was considered seropositive for a given HPV type if her serum antibody titer by cLIA for the HPV type was greater than the serostatus cutoff. The serostatus cutoffs for HPV Types 6, 11, 16, 18, 31, 45, 52, and 58 were 20, 20, 20, 20, 16, 16, 20, and 16 mMU/mL, respectively.","groups":[{"description":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) for Phase A","id":"OG000","title":"qHPV (GARDASIL™) - Phase A Control"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 15 mcg ISCOMATRIX™(IMX)","id":"OG001","title":"Octavalent HPV With 15 mcg IMX / AAHS"},{"description":"Octavalent Human Papillomavirus (HPV) (Types 6, 11, 16, 18, 31, 45, 52, and 58) L1 Virus-Like Particle (VLP) Vaccine Adjuvanted With 281 mcg Amorphous Aluminum Hydroxyphosphate Sulfate (AAHS) and 30 mcg ISCOMATRIX™ (IMX)","id":"OG002","title":"Octavalent HPV With 30 mcg IMX / AAHS"}],"paramType":"NUMBER","populationDescription":"PPI population: All participants who were not protocol violators, received all 3 vaccinations within acceptable day ranges, were seronegative at Day 1 and PCR-negative Day 1 through Month 7\n\nfor the relevant HPV type(s), and had a valid Month 7 serology result collected in the appropriate day range.","reportingStatus":"POSTED","timeFrame":"4 weeks postdose 3 (Phase A)","title":"Number of Participants Who Seroconverted to Each of the HPV Types Contained in the Vaccine During Phase A","type":"PRIMARY","unitOfMeasure":"Participants"}